Subsidiary of Budweiser-maker Anheuser-Busch to invest $300-million in U.S. facilities
Anheuser-Busch InBev's BUD-N American subsidiary said on Monday it would invest $300-million in its manufacturing operations in the United States this year amid a push for local production under President Donald Trump.
The St. Louis, Missouri-based Anheuser-Busch, which said it invested nearly $2-billion over the last five years in 100 facilities across the country, also announced the launch of a new plant in Columbus, Ohio.
'Anheuser-Busch has been a shining example of what 'Made in America' means, and their latest investment of $300-million builds on their longtime commitment to grow our workforce and expand U.S. manufacturing,' U.S. Labor Secretary Lori Chavez-DeRemer said.
AB InBev reported a rise in first-quarter profit last week that was more than double the increase expected by analysts. Its profit margins were also higher despite a fall in sales volumes.
The company had previously said it was boosting investments in key brands such as Budweiser and ramping up efforts to grow at-home consumption, as spending elsewhere – including in bars – remains pressured.
U.S.-listed shares of Anheuser-Busch were down 1.7 per cent in midday trading.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
Insider Buying and Options Surge Spark Bullish Interest in UnitedHealth (UNH)
UnitedHealth Group (UNH) is drawing attention from traders after a spike in call option activity and notable insider buying. Despite the stock being down nearly 40% year-to-date, a weaker-than-expected Q1 earnings report, and a softer outlook, recent activity suggests growing confidence in a potential recovery. Confident Investing Starts Here: Heightened Activity Signals Bullish Sentiment On Thursday, more than 162,000 call options were traded on UNH. That's a 29% jump compared to the stock's typical daily call volume of around 126,000. This level of activity often reflects bullish expectations from traders anticipating upward price movement. Insiders are also showing conviction. On May 14, Director John H. Noseworthy purchased 300 shares at an average price of $312.16. Six days later, CEO Stephen Hemsley bought 86,700 shares at an average of $288.57 per share, totaling over $25 million. In total, insiders have acquired 109,408 shares over the past 90 days, worth approximately $31.6 million. Insider buying of this scale often signals confidence in long-term value. Institutional investors have also been increasing their exposure to these assets. Vanguard, Wellington Management, and Norges Bank all added to their positions last quarter. Institutional ownership now stands at 87.9%, highlighting continued support from long-term holders. Stock Rebounds Slightly as Fundamentals Show Mixed Signals The stock closed Friday at $303.22, up 2.49% on the day. It remains far below its 52-week high of $630.73 and just above the recent low of $248.88. At current levels, UNH has a market cap of about $275 billion, a P/E ratio of 14.11, and a dividend yield of 2.84%. The company recently raised its quarterly dividend to $2.21 per share. UnitedHealth posted Q1 revenue of $109.6 billion, slightly below consensus estimates. Earnings per share came in at $7.20, missing expectations of $7.29. While analysts still expect full-year EPS of $29.54, several firms have lowered their price targets in response to the softer results and rising sector concerns. Options market data reinforces the bullish tilt. The put/call ratio is 0.48, indicating more call buying than put buying. This ratio suggests traders are positioning for a potential rebound in the near term. In summary, while UnitedHealth continues to face pressure from weaker earnings and macroeconomic headwinds, the surge in call option activity, insider buying, and strong institutional support indicate renewed investor interest. Is UNH a Good Stock to Buy Right Now? According to The Street's analysts, UnitedHealth is a Moderate Buy. The average UNH price target is $369.73, implying a 21.93% upside. See more UNH analyst ratings Disclaimer & Disclosure Report an Issue
Globe and Mail
20 minutes ago
- Globe and Mail
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025. The Company remains actively engaged with the U.S. Food and Drug Administration (FDA), with a 510(k) decision now expected during the third quarter of this year. This updated FDA decision timeline remains within the FDA's original scheduled review window and is not expected to affect the Company's planned launch upon clearance. 'Our recent interactions with the FDA have been productive, and we remain confident in the process and outcome,' said Harel Gadot, Chairman, CEO & President. 'We continue to operate with full momentum and position the Company for an anticipated launch during the third quarter of this year, which includes the continued build out of our commercial infrastructure and preparing the organization to deliver on our strategy.' As part of the Company's ongoing launch preparation, it recently expanded its commercial team with the addition of Michael Lytle as the head of Sales Operations & Analytics. Mr. Lytle brings deep experience in sales support, data analysis, and operational excellence. He is expected to play a key role in shaping market intelligence tools and processes to optimize the sales cycle and drive strategic growth. Prior to joining Microbot, Mr. Lytle held increasing leadership roles at ZOLL Cardiac Management Solutions (CMS), a division of ZOLL Medical Corporation, where he supported the rollout of innovative cardiac care technologies. 'We believe that Michael's addition will strengthen our launch readiness plans, and that his expertise will help us target the right markets, allocate resources effectively, and accelerate commercial execution,' concluded Mr. Gadot. The LIBERTY System is currently under FDA review, is not available for sales in the US, and clearance is not guaranteed. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical® is available at Safe Harbor Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as 'will,' 'believes,' 'plans,' 'anticipates,' 'expects' and 'estimates') should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading 'Risk Factors' in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law
Globe and Mail
20 minutes ago
- Globe and Mail
Chevron's Texas Job Cuts: What's Really Driving the Layoffs?
Chevron Corporation CVX is moving forward with significant layoffs in Texas, shedding roughly 200 positions in Midland by July 15, 2025. This round of job cuts is part of the oil giant's broader global restructuring plan, targeting a 15% to 20% reduction in headcount, up to 9,000 employees, by the end of 2026. While Chevron initially reported 799 job losses in Midland to the Texas Workforce Commission, the figure was later revised due to a data error. Most of the affected roles are based at Chevron's Mid-Continent campus on Deauville Boulevard, with additional cuts across nearby operational sites. The company's rationale is clear: simplify the operating structure, increase execution speed, and maintain long-term competitiveness. As Chevron integrates new technologies and rethinks where and how work gets done, it aims to centralize key functions and expand its global service hubs. For Midland, a critical point in Chevron's Permian Basin footprint, signals a shift toward leaner on-the-ground operations and heavier reliance on centralized decision-making. Chevron is offering severance and transition assistance, but the scale and cadence of layoffs across California and Texas highlight just how deep its cost-cutting agenda runs. With more cuts expected through 2026, Chevron's restructuring may redefine how it operates across key U.S. basins. How Other 'Big Oil' Peers Are Reshaping Their Workforces ExxonMobil XOM, Chevron's primary competitor, has taken a deliberate and methodical path in reshaping its workforce, steering clear of sweeping layoffs seen elsewhere in the industry. Rather than focusing on broad structural cuts, ExxonMobil ties reductions to individual and business performance, with most changes occurring outside the U.S. Over the past two years, ExxonMobil has quietly trimmed headcount while leaning on technology to streamline operations globally. European supermajor Shell SHEL has also been undergoing workforce transformation. After Shell's new CEO, Wael Sawan, took office, the company has been focusing on creating more value for its shareholders by improving its performance and simplifying its business operations. A central element of Shell's strategy involves streamlining operations and consolidating management to reduce expenses, with a particular focus on regions where operating costs are higher. CVX's Price Performance, Valuation and Estimates Shares of Chevron have lost around 3% year to date. From a valuation standpoint, Chevron's forward 12-month P/E multiple stands at over 18X, well above the subindustry. CVX carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Chevron's 2025 earnings implies a 32% decline year over year. The stock currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report Shell PLC Unsponsored ADR (SHEL): Free Stock Analysis Report This article originally published on Zacks Investment Research (
